Celldex Therapeutics, Inc.
CLDX
$18.30
$0.502.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.02M | 9.98M | 8.30M | 6.07M | 6.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.02M | 9.98M | 8.30M | 6.07M | 6.88M |
| Cost of Revenue | 127.75M | 111.23M | 100.51M | 99.11M | 94.25M |
| Gross Profit | -120.73M | -101.26M | -92.20M | -93.04M | -87.37M |
| SG&A Expenses | 38.55M | 37.12M | 35.28M | 33.38M | 30.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.10M | 184.15M | 171.59M | 156.25M | 148.93M |
| Operating Income | -195.08M | -174.18M | -163.29M | -150.18M | -142.04M |
| Income Before Tax | -157.86M | -154.08M | -150.22M | -144.88M | -141.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -157.86 | -154.08 | -150.22 | -144.88 | -141.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.86M | -154.08M | -150.22M | -144.88M | -141.43M |
| EBIT | -195.08M | -174.18M | -163.29M | -150.18M | -142.04M |
| EBITDA | -191.90M | -171.06M | -160.19M | -147.12M | -139.03M |
| EPS Basic | -2.45 | -2.57 | -2.74 | -2.84 | -2.91 |
| Normalized Basic EPS | -1.53 | -1.45 | -1.56 | -1.63 | -1.67 |
| EPS Diluted | -2.45 | -2.57 | -2.74 | -2.85 | -2.91 |
| Normalized Diluted EPS | -1.53 | -1.45 | -1.56 | -1.63 | -1.67 |
| Average Basic Shares Outstanding | 257.54M | 243.21M | 224.18M | 205.41M | 193.76M |
| Average Diluted Shares Outstanding | 257.54M | 243.21M | 224.18M | 205.41M | 193.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |